OBJECTIVE: The purpose of this study was to define the pharmacokinetic parameters of 17-hydroxyprogesterone caproate (17-OHPC) in multifetal gestation. STUDY DESIGN: Blood was obtained at 24-28 weeks' gestation and at 32-35 weeks gestation in 97 women with twin and 26 women with triplet gestation who were receiving 17-OHPC. Six of the women with twins had daily blood sampling for 7 days between 24 and 28 weeks' gestation, and pharmacokinetic parameters were estimated with the use of noncompartmental analysis. Modeling was applied to estimate the population parameters and to simulate various treatment scenarios. RESULTS: The apparent half-life of 17-OHPC was 10 days. Body mass index significantly impacted 17-OHPC concentrations, but fetal number and parity did not. Apparent clearance was significantly greater in African American than in white women (P = .025). CONCLUSION: This is the first pharmacokinetic analysis of 17-OHPC in pregnant women. Determination of half-life, covariates that affect plasma 17-OHPC concentrations, and the modeling of drug behavior provide insights into this drug's pharmacologic properties during multifetal pregnancy.
OBJECTIVE: The purpose of this study was to define the pharmacokinetic parameters of 17-hydroxyprogesterone caproate (17-OHPC) in multifetal gestation. STUDY DESIGN: Blood was obtained at 24-28 weeks' gestation and at 32-35 weeks gestation in 97 women with twin and 26 women with triplet gestation who were receiving 17-OHPC. Six of the women with twins had daily blood sampling for 7 days between 24 and 28 weeks' gestation, and pharmacokinetic parameters were estimated with the use of noncompartmental analysis. Modeling was applied to estimate the population parameters and to simulate various treatment scenarios. RESULTS: The apparent half-life of 17-OHPC was 10 days. Body mass index significantly impacted 17-OHPC concentrations, but fetal number and parity did not. Apparent clearance was significantly greater in African American than in white women (P = .025). CONCLUSION: This is the first pharmacokinetic analysis of 17-OHPC in pregnant women. Determination of half-life, covariates that affect plasma 17-OHPC concentrations, and the modeling of drug behavior provide insights into this drug's pharmacologic properties during multifetal pregnancy.
Authors: Dwight J Rouse; Steve N Caritis; Alan M Peaceman; Anthony Sciscione; Elizabeth A Thom; Catherine Y Spong; Michael Varner; Fergal Malone; Jay D Iams; Brian M Mercer; John Thorp; Yoram Sorokin; Marshall Carpenter; Julie Lo; Susan Ramin; Margaret Harper; Garland Anderson Journal: N Engl J Med Date: 2007-08-02 Impact factor: 91.245
Authors: Barbara J Attardi; Anthony Zeleznik; Hyagriv Simhan; Jye Ping Chiao; Donald R Mattison; Steve N Caritis Journal: Am J Obstet Gynecol Date: 2007-12 Impact factor: 8.661
Authors: Lisa M Foglia; Danielle L Ippolito; Jonathan D Stallings; Craig M Zelig; Peter G Napolitano Journal: Am J Obstet Gynecol Date: 2010-09-01 Impact factor: 8.661
Authors: J M O'Brien; C D Adair; D F Lewis; D R Hall; E A Defranco; S Fusey; P Soma-Pillay; K Porter; H How; R Schackis; D Eller; Y Trivedi; G Vanburen; M Khandelwal; K Trofatter; D Vidyadhari; J Vijayaraghavan; J Weeks; B Dattel; E Newton; C Chazotte; G Valenzuela; P Calda; M Bsharat; G W Creasy Journal: Ultrasound Obstet Gynecol Date: 2007-10 Impact factor: 7.299
Authors: Andrei Rebarber; Jane Cleary-Goldman; Niki B Istwan; Debbie J Rhea; Cheryl Desch; Karen Russo-Stieglitz; Daniel H Saltzman Journal: Am J Perinatol Date: 2008-04-09 Impact factor: 1.862
Authors: Amy L Turitz; Jamie A Bastek; Stephanie E Purisch; Michal A Elovitz; Lisa D Levine Journal: Am J Obstet Gynecol Date: 2015-10-28 Impact factor: 8.661
Authors: Steve N Caritis; Raman Venkataramanan; Elizabeth Thom; Margaret Harper; Mark A Klebanoff; Yoram Sorokin; John M Thorp; Michael W Varner; Ronald J Wapner; Jay D Iams; Marshall W Carpenter; William A Grobman; Brian M Mercer; Anthony Sciscione; Dwight J Rouse; Susan Ramin Journal: Am J Obstet Gynecol Date: 2013-10-07 Impact factor: 8.661
Authors: Steve N Caritis; Shringi Sharma; Raman Venkataramanan; Gary D Hankins; Menachem Miodovnik; Mary F Hebert; Jason G Umans; Thomas Benedetti; Donald Mattison; Anne Zajicek; Dawn Fischer; Aimee Jackson Journal: Am J Obstet Gynecol Date: 2012-08-16 Impact factor: 8.661
Authors: Shringi Sharma; Ewa C S Ellis; Roberto Gramignoli; Kenneth Dorko; Veysel Tahan; Marc Hansel; Donald R Mattison; Steve N Caritis; Ronald N Hines; Raman Venkataramanan; Stephen C Strom Journal: Drug Metab Dispos Date: 2012-11-05 Impact factor: 3.922
Authors: Tracy A Manuck; Lisa Smeester; Elizabeth M Martin; Martha S Tomlinson; Christina Smith; Michael W Varner; Rebecca C Fry Journal: Am J Perinatol Date: 2017-12-14 Impact factor: 1.862